clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3
Muscle spasms for NCT01217749 [clinicaltrials_resource:00000e8656f10ada35713bb2979c8956]Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 Baseline (Week 0) and Week 8 [clinicaltrials_resource:0000118aa46e7c26af559737dc5be2b4]eligibility for clinicaltrials:NCT00192504 [clinicaltrials_resource:00001abf5ed6267d2c8aa8fb45b0604a]negative pregnancy test for women able to have children [clinicaltrials_resource:00001d8e827435c8e93afb66f500fcb8]Abdominal Cramps for NCT00935493 [clinicaltrials_resource:000025c442238877473f032074bb726e]Number of Participants With Overall Response (OR), as Assessed by the Investigator From the start of study treatment until 3 months after the last dose of study treatment [clinicaltrials_resource:000026652b72c8457ecae4232ef7819b]eligibility for clinicaltrials:NCT00002392 [clinicaltrials_resource:000034aca54e0278f73c7b72fefc8f39]Overall response rate of initial treatment with SCH 727965 in subjects with AML or ALL. Time to identified response or disease progression on SCH 727965 in Part 1 (approx. 5 months). [clinicaltrials_resource:000036d07b2489619e85b7dcd5e0f736]7-day point prevalence smoking abstinence verified by saliva cotinine taken post-intervention (8 weeks after baseline) [clinicaltrials_resource:00003aa5b9e3db40e06a7d66e7826d47]concurrent chemoradiotherapy plus DC-CIK immunotherapy [clinicaltrials_resource:00003d01e7c79d0213aa2f1a36628c19]Gait 12 weeks [clinicaltrials_resource:00003dcf43e1c3f68115efa8e9ce1941]No prior New York Heart Association class I-IV heart disease [clinicaltrials_resource:00003e83924167ab147f1d1c1b4593d2]Dexamethasone [clinicaltrials_resource:00004030a9ebe5d5f6830bff83e982cb]serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min [clinicaltrials_resource:0000411ab9e3c4561cb8829c6124638e]Esko Ruokonen, MD [clinicaltrials_resource:0000449702632e4e5d5b88428b1c285e]Doczero [clinicaltrials_resource:0000479ef685db9bbf5ad98ac3d11cf4]Hemoglobin < 12.0 g/dL [clinicaltrials_resource:00004f03d23b4d71b15234f2e1863411]Stephen Robinson, FRCP, MD [clinicaltrials_resource:00005798f671f645ac3b79153a68b763]Antibody Concentrations Against Pneumococcal Vaccine Serotypes One month after the administration of the 3rd vaccine dose i.e. Month 5 [clinicaltrials_resource:000057dd7c420208c0b09c4fdc3fcf19]Chemotherapy/Cell
Infusion).
18. Serum ALT less than three times the upper limit of normal. (Turnstile II -
Chemotherapy/Cell Infusion- Inclusion Criteria).
19. Serum creatinine less than or equal to 1.6 mg/dl. (Turnstile II [clinicaltrials_resource:00005bb5a8a13d989221656efc37828d]Time to Last Unformed Stool (TTLUS) 48 hours [clinicaltrials_resource:00005ec47c408d18cf469b6bfc96c212]6-month Progression-free Survival 6 months after first dose [clinicaltrials_resource:000064868dd7d872c050c90eb2d4ab96]Myocardial infarction for NCT00878800 [clinicaltrials_resource:000066de1c8074e05477b17c22f20daa]Alcohol poisoning for NCT00492063 [clinicaltrials_resource:00006c6a2177b9e898c95051d822e5bd]Fungal infection for NCT00460798 [clinicaltrials_resource:00006ff798dc8469f2dcbc0a731733c5]HAMD-17 total score at week 8. Tolerability. at week 8 [clinicaltrials_resource:000077b7624960148a0e79c37e613806][clinicaltrials_resource:00007f016afdb489841b85355589b969]Randall R. Rule, PhD [clinicaltrials_resource:000085c7d0b1239ccf88c845fd1c0082]Asthenia for NCT00833638 [clinicaltrials_resource:000086644bb19222b711fa8acacc3d33]Persistance and adherence to treatment 2 years [clinicaltrials_resource:0000877790ab42df9b393fc0772dd1b4]Daily GC (prednisone or deflazacort) therapy for > 12 months [clinicaltrials_resource:0000907adbe4924012b8acaf5fe7481b]Oedema, Pulmonary [clinicaltrials_resource:000096cc1e8e591fdddd5b90037b369b]Pyelonephritis for NCT01183013 [clinicaltrials_resource:000097011233c2c2ae3769cc1db63e0c]clinicaltrials:NCT00955383 study design [clinicaltrials_resource:0000a927a89929d9e25957fee1d004a1]Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left
anterior or posterior fascicular block; ventricular premature beat; first degree
atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T
changes; abnormal Q waves; low voltage QRS; or atrial fibrillation); [clinicaltrials_resource:0000b2f11bbe7d9c32ae396cacebeee8]clinical results for clinicaltrials:NCT01660763 [clinicaltrials_resource:0000b40bab963f64766737680acfe895]Modified Mayo Score indicating remission Week 12 and Week 24 [clinicaltrials_resource:0000b6f1b6b4d159c16e3abcf84587cf]eligibility for clinicaltrials:NCT01514175 [clinicaltrials_resource:0000b7a84af0c468b75fac24df4074c8](2)Fatty liver was diagnosed by abdominal echo by the same gastrologist, review by
another gastrologist [clinicaltrials_resource:0000bbd49a0f79c3cb6904d48e52bf86]Arun Rao [clinicaltrials_resource:0000bc73ada51aac863a10597a3ba978]